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s ince its introduction in 1953 by Child hepatic glycogen storage disease and portal 
and  associate^,^ the experimental procedure 
of portacaval transposition has received in- 
tensive study in many laboratories. Such in- 
vestigations have shown that portacaval 
transposition can be performed in dogs with 
relatively small  risk,'^ 32 that animals so al- 
tered can live for long periods of time in 
good health, and that hepatic function tests 
are not deranged,3, sl  29, 31 except for ab- 
normalities of response to oral ammonia 
10ads.~" Although gastric hyperacidity has 
been shown to be a consequence of the opera- 
tion,4, 5, 20, 25, 30 this has not proved to be the 
cause of long-term morbidity in dogs. 
In this communication a previously unre- 
ported result of portacaval transposition in 
dogs will be described-that of hepatic de- 
glycogenation. The observation that a sub- 
stantial reduction in hepatic glycogen content 
follows portacaval transposition in dogs 
prompted the use of this operative procedure 
for the treatment of an 8-year-old child with 
Aided by United States Public Health Service Grants 
AM 06283. A 6344, HE 07735, AM 07772, FR 00051, 
and GM 04761. 
Submitted for publication Sept. 30, 1964; resubmitted 
Jan 15, 1965. 
'Markle Scholar. 
cirrhosis. 
METHODS 
Animal studies. A total of 45 mongrel dogs 
weighing 7.0 to 22.7 kilograms were used. 
Seventeen animals, employed in hepatic gly- 
cogen studies, underwent portacaval trans- 
position by means of a rnodificati~n~~ of 
Child's3 method. Thirteen of these 17 dogs 
also had ligation of all venous tributaries to 
the ileocaval system from the inguinal liga- 
ments to the diaphragm, with the single ex- 
ception of the renal veins, in order to pre- 
vent the uncontrolled development of sys- 
temic venous collaterals. Since the results of 
hepatic deglycogenation were similar in those 
groups which did and those which did not 
have this additional procedure, the results 
from all 17 experiments were ultimately 
pooled for analysis. Four additional control 
dogs had a sham operation in which the same 
dissection was carried out. The portal vein 
was then occluded for 10 minutes and the 
inferior vena cava for 20 minutes, times com- 
parable to those required for the perfor- 
mance of the actual transposition in the test 
group. 
.- - 
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After a 20 hour fast, open liver biopsies 
were obtained under sodium pentobarbital 
anesthesia at the time of, and 36 to 75 days 
after, transposition or sham operation. The 
liver tissue was immediately frozen on dry ice 
and analyzed in Denver for glycogen content. 
The method of Bloom and his associates1 was 
used to separate the trichloroacetic acid 
(TCA) soluble frorn the TCA insoluble frac- 
tions. Quantitative determination of these 
glycogen fractions was then carried out by 
the anthrone method of Seifter and his as- 
sociate~.?~ Results were expressed as milli- 
grams of glycogen per gram of wet liver tis- 
sue. 
After a period of training, oral glucose 
tolerance tests were performed in the un- 
anesthetized state 2 days before the pre- and 
posttransposition biopsies in all 17 dogs of the 
test group. The glucose dose of 0.5 Gm. per 
kilogram was qiven in solution by gastric 
intubation. Plasma glucose was measured 
with an autoanalyzer. Before transposition, 
the hyperglycemic response to oral glucose 
was measured only in the femoral vein. Post- 
operatively, simultaneous specimens were ob- 
tained from an artery, the femoral vein, and 
the distal portal vein via a multiple-catheter 
sampling t e ~ h n i q u e . ~ ~  
In  another group of 24 animals weighing 
7.0 to 2 1.5 kilograms, transposition and liga- 
tion of ileocaval venous collaterals were car- 
ried out. Four to 12 weeks later, the effect 
of constant intravenous glucagon infusion 
(15 mcq. in 45 minutes) was measured, com- 
paring the effect of transfemoral (intra- 
portal) administration with that observed 
with the systemic (via a foreleg vein) route. 
The tests with fore- and hind-leg vein glu- 
cagon infusion were performed one week 
apart in randomized order. 
Human studies. Detailed analysis of the 
biochemical defect in the patient with gly- 
cogen storage disease was carried out before 
and 8% months after portacaval transposi- 
tion, following a 7 hour fast. Biopsies of the 
liver and the rectus muscle were immedi- 
ately frozen on dry ice and subsequently 
analyzed in St. Louis for glycogen content 
and enzymatic activity. Glycogen was iso- 
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lated from alkaline digests of the tissues and 
the structures of the polysaccharide prepara- 
tions were determined by differential enzy- 
matic degradation with phosphorylase and 
amy10-1,6-glucosidase.~~ 
Homogenates of the liver and muscle were 
assayed for glu~ose-6-phosphatase,~~ liver 
phosphorylase, muscle phosphorylase, a-glu- 
cosidase,ll UDPG glycogen synthetase and 
amylo-1,6-glucosidase. Amylo- 1,6-glucosidase 
was determined with the widely used method 
of Hers," as well as with a recently described 
technique.14, '' 
In  addition, red cell glycogen content was 
measured.27 Serum lipids were determined in 
the following fractions: cholesterol and esters, 
fatty acids, nonesterified fatty acids, phospho- 
lipids, and neutral fats. Urine steroids and 
catechol levels were determined (by Dr. Dal- 
ton Jenkins) . Quick one-stage prothrombin, 
specific prothrombin and proconvertin, ac- 
celerator globulin, and Stuart assay were per- 
formed. Numerous standard liver function 
tests were measured and the responses to oral 
glucose, intravenous glucagon, and various 
gastric stimulants are described below. The 
size of the liver and of the spleen were de- 
termined before and after operation with a 
liver scan technique employing radioactive 
gold. 
RESULTS 
Effect of transposition upon hepatic gly- 
cogen content. Fourteen of the 17 dogs stud- 
ied had reduction in hepatic glycogen con- 
tent 45 to 75 days after transposition. The 
total glycogen decreased an average of 5 1 per- 
cent (Fig. 1) .  The principal loss was in the 
TCA soluble glycogen, the mean decrease 
being 70 per cent. TCA insoluble glycogen 
decreased an average of only 11 percent. The 
changes in total and TCA soluble glycogen 
were significant at the 2 percent (p  < .02) 
and 1 percent ( p  < .01) levels, respectively. 
The change in TCA insoluble glycogen was 
not significant. 
Effect of sham operation upon hepatic gly- 
cogen content. The 4 control dogs had a 
mean total hepatic glycogen content of 30.6 
mg. per gram wet liver tissue; TCA soluble 
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Fig. 1. Mean changes in liver gly- 
cogen fractions in 17  dogs following 
transposition. Vertical lines represent 
'1 standard error. 
TOTAL GLYCOGEN 
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GLYCOGEN GLYCOGEN 
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TRANSPOSITION TRANSPOSITION 
glycogen, of 20.9 mg. per gram; and TCA 
insoluble glycogen, of 9.6 mg. per gram. 
These figures were almost identical to those 
recorded in the test group. Thirty-six days 
after the sham operation, total hepatic gly- 
cogen content was increased in all 4 animals. 
The mean TCA soluble fraction was 50.9 
mg. per gram, the TCA insoluble fraction 
was 10 mg. per gram, and the total glycogen 
was 60.9 mg. per gram. The increase in TCA 
soluble glycogen is probably due to the better 
Fig. 
pre- 
the 
2. Venous plasma glucose changes 
and posttransposition following 
intra~astric administration of 0.5 
diet available to the animals in the laboratory 
than had been their usual fare. The increased 
glycogen content observed in the control 
group lends increased significance to the de- 
creases noted in the test animals, which were 
obtained from the same sources and treated 
in the same way. 
Effect of portacaval transposition upon 
glucose tolerance test. The effect upon pe- 
ripheral venous blood of the same oral glu- 
cose load before and after operation is de- 
- PRE TRANSPOSI'IION 
,--, POST TRANSPOSITION 
., 
Gm. glucose per kilogram body 
weight. Means from 17 dogs. Vertical 
lines represent +1 standard error. 
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picted in Fig. 2. The magnitude of the hyper- 
glycemic response was almost halved after 
operation, and the duration of the rises in 
blood sugar was somewhat lessened. The dif- 
ferences were of borderline significance ( p  
< 0.1 ) . After transposition, the postprandial 
hyperglycemia was considerably greater in 
the splanchnic venous drainage than in the 
peripheral arteries or femoral vein. 
Effect of glucagon infusion in dogs with 
portacaval transposition. With portal infu- 
sion (via the femoral vein) the hyperglycemic 
response was greater (Fig. 3 )  than with glu- 
cagon infusion into a foreleg vein. The differ- 
ence in effect by the two routes of adminis- 
tration was significant at the 1 percent level 
( p  < .01). 
CLASSIFICATION O F  
GLYCOGENOSIS 
Glycogen storage diseases are hereditary 
disorders of carbohydrate metabolism which 
have been classified on the basis of demm- 
strated enzymatic deficiencies7, 11, l2 T YPe I 
glvcogenosis is characterized by a deficiency 
of glucose-6-phosphataseG; Type I1 by a lack 
of a-glucosidasel1; Type I11 by a deficiency 
of arnylo-1,6-glucosidase"; Type 1V by a 
presumed deficiency of the branching en- 
~ y m e ' ~ ,  28; Type V by a lack of muscle phos- 
phorylase", '\ and Type VI  of unknown 
etiology, but primarily affecting the liver. 
The case described below involved an amylo- 
1,6-glucosidase deficiency. 
Fig. 3. Arterial plasma glucose changes 
during and following 45 minute infusions 
of 15 mcg. of crystalline glucagon by two 
different routes. Mean changes from 24 
dogs. Vertical lines represent 21 standard 
error. 
CASE REPORT 
The patient, an 8%-year-old girl, was born on 
Fcb. 13, 1955, the product of a normal pregnancy. 
An older brother is healthy. The child's maternal 
grandmother died of cirrhosis of the liver at  the 
age of 44. During the first few months of life the 
child had abdominal swelling, irritability, and con- 
stipation. The diagnosis of glycogen storage disease 
was made from an open liver biopsy at the age of 
7 months. During the first 8 years of her life 
pronounced hepatomcgaly was present, the liver 
being palpable from 5 to  7 cm. below the right 
costal margin. Splenomcgaly became increasingly 
prominent. At the ages of 1, 2, and 5 years, the 
patient had relatively severe convulsivc episodes 
lasting from 1 to 2 hours, which were relieved on 
each occasion with an intravenous glucose infusion. 
Blood sugars were not determined a t  these times. 
She was maintained on a high protein, high carbo- 
hydrate diet with multiple nocturnal feedings. 
From the age of 3, she suffered from frequent nose 
bleeds and easy bruisability. At the age of 6, she 
had a relatively severe hematemesis, the cause for 
which was not determined. Her principal com- 
plaint before admission to Colorado General Hos- 
pital on Sept. 20, 1963, was enlargement of the 
abdomen that made ambulation difficult. 
Physical examination. A large, upper abdominal 
mass was palpable 7 cm. below the right costal 
margin and 9 cm. below the left costal margin. 
There were a number of scattered ecchymoses on 
both legs, thighs, and over the lower abdomen. 
The child was of short stature. 
Laboratory examination. Hematocrit was 30 
percent, white count 4,000 per mm.,3 and platelet 
count 88,000. Urinalysis was normal. Thymol tur- 
bidity was 4.0 and serum bilirubin 1.8 mg. percent, 
with 0.5 mg. percent conjugated. Alkaline phos- 
phatase was 6.7 Bodansky units and SGOT was 
220 SF units. The quick prothrombin time ranged 
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Fig. 4. Biopsies 2 weeks before and 8% months after portacaval transposi- 
tion. Note the foamy appearance of the glycogen-laden hepatocytes in both 
specimens, as well as the evidence of cirrhosis. A, Preoperative, B, post- 
operative. (Hematoxylin and eosin. Original magnification ~ 3 2 . )  An in- 
crease in mononuclear cells in the periportal areas is present in the second 
specimen. 
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Table I .  Enzymatic activities of homogenates prepared from liver and muscle 
biopsies o f  the  patient treated with portacaual transposition 
(activities i n  pmoles substrate utilized per minute per gram tissue) 
a-glucosidase 
Liver 
October, 1963 July, 1964 
Amylo- l,6-glucosidase 0 0 ,042 ,047 
(0.04-0.18) (0.03-0.07) 
Muscle 
October, 1963 ( July, 1964 
Phosphorylase 
UDPG glycogen synthetase 1.1 3.0 1.8 2.7 
(1.4-3.5) ( 1.5-3.9) 
Glycoeen content 10.1 per cent 9.7 per cent 1.6 per cent 1.2 per cent 
*The figures in parentheses are the normal range. 
400 mcg. per gram Hgb. (normal, 22 to 109 mcg. 
per gram Hgb.) . Seven fasting blood sugar evalua- 
tions were made; the lowest value recorded was 
55 mg. percent and the highest was 87 mg. per- 
cent. Urinary steroids and catecholamines were 
normal. 
Chcst x-ray and electrocardiogram were nor- 
mal. The liver scan and other x-rav studies showed 
a greatly enlarged liver as well as splenomegaly. 
Esophageal varices or duodenal ulcer could not be 
seen with a gastrointestinal series. An intravenous 
pyelogram showed slightly enlarged kidneys. 
O n  Sept. 30, 1963, muscle and liver biopsies 
were obtained. Histologically, the liver tissue ap- 
peared to have a high glycogen content, and there 
was moderatcly severe portal cirrhosis (Fig. 4 , A ) .  
The hepatic glycogen content was elevated (10.1 
percent). 'The muscle glycogen content was normal 
( 1.6 percent). Amylo-1,6-glucosidase activity was 
absent in thc liver homogenates, whereas a signifi- 
cant degree of activity was demonstrable in the 
musclc. Glucose-6-phosphatase, muscle phosphory- 
lase, UDPG glycogen synthetase, and a-glucosidase 
were not abnormal. Liver phosphorylase was 
slightly depressed.* These data established the 
diagnosis of Type 111,- B glycogen storage disease 
(Table I ) .  
Portacaval transposition. The child underwent 
portacaval transposition and total-body hypother- 
mia of 30" C. A thoracoabdominal incision was 
made (Fig. 5 ) .  Upon entering the abdomen, 
numerous serpiginous venous collaterals were seen 
'Full details of the analytic methods and interpretation 
of results will be provided upon request to Dr. Barbara 
Illingworth, Department of Biological Chemistry, Wash- 
ington University School of Medicine, St. Louis. 
on the abdominal wall, in the retroperitoneal 
space, and in the portal triad. The portal vein was 
dissected free from the pancreas to just below its 
division in the liver hilum and the inferior vena 
cava was cleaned off from the renal veins to the 
liver. Both vessels were then grasped with Potts 
clamps as far proximally and distally as possible 
and the vessels were transected (Fig. 5,B). I t  had 
been planned to use external bypass from the in- 
ferior to the superior vena cava during the time 
of vascular occlusion, but application of the clamps 
on both vessels did not cause any fall in blood 
pressure or rise in pulse and this step was there- 
fore omitted. Anastomosis of the distal portal vein 
to the proximal vena cava was performed first 
(Fig. 5,C) and anastomosis of the distal vena cava 
to the proximal vcin performed next (Fig. 5,D). 
There were no technical difficulties nor any undue 
tension on the reconstructed vessels. 
Response to portacaval transposition. There was 
rapid recovery from the operative procedure and 
the patient was discharged on the ninth postopera- 
tive day. Swelling of the lower extremities was 
not observed. Venograms 3 months after operation 
demonstrated patency of the anastomosis (Fig. 6 ) .  
There was no disturbance of renal function, all 
postoperative blood urea nitrogcn values and crea- 
tinine clearances ((20") being normal. A number of 
studies were performed 3 weeks, and 3, 8%, and 
11 months postoperatively. 
The abnormalities in liver function present be- 
fore operation have been relatively unchanged. 
Postoperative serum bilirubins, prothrombin times, 
SGOT, thymol turbidity, plasma proteins, serum 
lipids, glucose tolerance, and glucagon tolerance 
have all remained essentially unchanged. Urine 
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Fig. 5. Technique of portacaval transpo- 
sition. The  operation was done under 
hypothermia. A, Incision; B, dissection 
completed and vessels transected; C, por- 
tacaval anastomosis performed first; D, 
the second anastomosis completed. 
steroids and catecholamines remained within nor- 
mal limits. 
Evidence of hypersplenism persisted postopera- 
tively, the white count ranging from 2,600 to 
8,200, and platelet counts from 40,000 to 180,000. 
Hematocrit has increased from 27 to 37 percent. 
Alterations in gastric secretion. A comparison 
of basal, peptone-induced, and histamine-induced 
gastric secretion are shown in Table I1 before and 
after transposition. Although there appeared to be 
a n  increased response to peptone broth stimulation, 
this was not a marked change and was unattended 
by alterations in basal secretion. The acid con- 
centration after maximal histamine stimulation ap- 
peared to be elevated, although this rise was ac- 
companied by low-volume secretion so that the 
total acid produced was essentially unchanged. 
T h e  long-term effect of transposition on gastric 
secretion will probably not be dissimilar to that 
which results from portacaval anastomosis. Post- 
operative gastrointestinal series was normal on 
Sept. 9, 1964. 
Analysis of postoperative liver biopsy. On  July, 
2,  1964, laparotomy was performed for liver biopsy. 
Histologic study of the section revealed somewhat 
more cirrhosis than was seen a t  the time of the 
first biopsy (Fig. 4 ,B ) ,  with more cellular infiltra- Fig. 6.  Inferior venocavagram performed 3 months 
tion in the periportal areas. Biochemical analysis after clinical portacaval transposition. The  porta- 
for glycogen content and structure and for enzyme caval anastomosis is indicated (arrow). Note that 
content were unchanged. some dye reaches the liver, but a large amount of 
Growth and development. The child, who the vena caval blood passes through paravertebral 
weighed 65 pounds prior to transposition, weighed collaterals. 
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One hour basal 
Table 11. Elqect of h u m a n  portacaval transposition u p o n  gastric secretion 
Peptone broth stimulation ( 1 hour) 
Maximum 30 minute histamine response* 48 59 5.6 
(15 to 45 minutes after histamine) 2 2 75.5 3.32 
2 0 104 4.2 
2 2 78  3.4 
2 5 100 5.0 
Note:  Results are listed chronologically within each test according to the followirl~ sequence: Oct. 9, 1963 (PI-eoperative); 
Nov. 8, 1963; Jan. 10, 1964; July 1, 1964; and Sept. 9, 1964. 
"Dose: 0.04 mg. per kilogram body weight of histamine acid pllosphate S.Q. 100 mg. Benadr~l was given intramuscu- 
larly 30 minutes before histamine. Note that histamine volume.; are for 30 minutes, but that HCI output is exp~essed per hour. 
Amount HCZ per 
hour (mEq.)  
74.2 pounds 11 months later. Her height, which 
was 49 inches, increased to 53% inches during 
this time (Fig. 7 ) .  O n  the Harvard growth chart 
these changes constituted a weight jump from the 
sixtieth to the seventy-fifth percentile, and a change 
from the tenth to the fiftieth percentile in height. 
Her abdominal girth was markedly reduced, due 
primarily to a reduction in spleen size. By physical 
examination and at re-exploration after 7 months, 
diminution in liver size was also noted, but this 
could not be objectively documented with a liver 
scan. The night feedings which she had reccived 
during most of her life were discontinued without 
harmful sequelae. She receives a regular diet. 
Fifteen postoperative fasting plasma glucoses have 
been obtained and these have ranged from 62 to 
75. She has had 3 or 4 upper respiratory infec- 
tions in the past year, all controllcd with the 
appropriate antibiotic therapy. 
HCZ (mEq. /L . )  Gastric secretion test 
DISCUSSION 
While it has been said by Silen and his 
associates2Qhat the liver of the dog with 
Eck fistula has a reduced glycogen content, 
the same authors did not believe that a simi- 
lar deglycogenation occurred after portacaval 
transposition. Failure to observe this effect 
may have been due to differences in method- 
ology, since these authors studied autopsy 
tissue by means of a histochemical determina- 
Volume (ml . )  
Fig. 7. Photographs of patient who underwc 
portacaval transposition taken one week before ( 
and 11 months after (B) operation. An idea 
the gain in height can be obtained, since the ch 
is wearing the same dress for both photographs, 
?nt 
A )  
of 
ild 
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tion which does not differentiate TCA solu- 
ble from TCA insoluble glycogen. Failure to 
freeze tissue immediately after biopsy is 
known to result in rapid changes of TCA 
soluble fraction.24 With rapid freezing of the 
biopsy tissue and quantitative biochemical 
analysis, a substantial reduction in hepatic 
glycogen was demonstrated in the present 
study, the principal loss being in the TCA 
soluble fraction. 
I t  is noteworthy that the same dogs which 
exhibited a loss of hepatic glycogen also had 
a change in the glucose tolerance test after 
transposition. The hyperglycemic response to 
an oral glucose load was of shorter duration 
and reduced intensity. This is in contrast to 
the finding after Eck fistula, in which a 
diabetic curve is e n c o ~ n t e r e d . ~ ~  
Despite the aforementioned changes in 
carbohydrate metabolism, the studies with 
glucagon infusion demonstrate the capacity 
of the liver for glycogenolysis. Very small 
doses of glucagon ( 15 mcg. total) delivered 
by constant infusion over a 45 minute period 
caused substantial hyperglycemic responses, 
either with hindlimb or forelimb infusion. 
The effect was greater with hindlimb infu- 
sion, in which at least part of the glucagon 
passed directly into the liver, a finding which 
is in accord with earlier studies.Vt is note- 
worthy that the child who received 10 to 30 
times as much glucagon per weight over a 
much shorter period of time did not respond 
with elevations in blood sugar. 
In the patient reported, the presence of 
portal cirrhosis, portal hypertension, and 
hypersplenisni constituted indications for de- 
compression of the splanchnic bed. That 
portal decompression can sometimes benefit 
patients with abnormal hepatic deposition of 
metabolites was demonstrated by Imparato,'" 
who performed an end-to-side portacaval 
anastomosis on a 10-year-old child with 
Gaucher's disease. The patient was proved 
by biopsy to have the abnormal depositions 
of cerebroside in the skeleton, testicle, spleen, 
mesenteric lymph nodes, and liver. The indi- 
cation for operation was the presence of mas- 
sive ascites, which was promptly relieved and 
which had not recurred 2% years later. I t  is 
Portacaval transposition and metabolism 695 
of interest that a reduction of hepatomegaly 
was incidentally observed postoperatively. 
Unfortunately, metabolic studies were not re- 
corded. 
The present case, which required portal 
decompression, also provided an unusual op- 
portunity to see whether changes in carbo- 
hydrate metabolism similar to those observed 
in dogs with transposition would occur in a 
patient with glycogen storage disease, recog- 
nizing that the enzyme deficiency in the child 
would diminish the degree of response. Thus 
the inherent capacity for glycogenolysis in 
the child would not be altered by the opera- 
tion, but the liver would be removed from 
the immediate portal hyperglycemia follow- 
ing meals, and more glucose would be made 
available for peripheral utilization. The pos- 
sible value of portal blood flow diversion for 
this purpose was suggested by Field.7 
Working with this hypothesis, the only 
suitable type of case would be that of the 
patient with an enzyme defect confined to 
the liver, in which case the liver would be 
placed in a more advantageous position, in 
that its reduced rate of glycogenolysis could 
be brought into closer conformity to the rate 
of glycogen storage. If enzyme defects are 
not present in other tissue, the result will 
not then be accelerated deposition of gly- 
cogen in the heart and muscles and kidneys. 
The child reported in the present study ful- 
filled these criteria. The only enzyme de- 
ficiency was amylo-1,6-glucosidase and the 
abnormal glycogen depots were confined to 
the liver. 
After portacaval transposition the child ap- 
peared to have been considerably benefited, 
with a marked decrease in the abdominal 
girth, a reduction in the size of the upper 
abdominal masses, a spurt in growth, and a 
marked increase in physical activity. While 
the hypersplenism is still present, there has 
been improvement, the most marked change 
being in the platelet count. 
I t  is possible that most or all of these 
effects were the consequence of the portal 
decompression, although the accelerated 
growth rate is not easily explained on this 
basis. Almost certainly the reduction in sple- 
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nomegaly was due to the relief of portal hy- 
pertension. The biochemical analyses per- 
formed before operation were essentially un- 
changed afterward, the enzyme concentra- 
tion and glycogen content of both liver and 
muscle being essentially the same. While a 
reduction in hepatomegaly did occur, it was 
not of great magnitude. It is possible that 
such a change in liver size would not be re- 
flected in the tissue analyses, since these were 
expressed in units per wet weight. Thus, al- 
though the concentrations of enzyme and 
glycogen might remain the same, this would 
not preclude an over-all decrease in the total 
amount of glycogen stored in the liver. 
In  the absence of more decisive evidence, 
however, it must be conceded that the out- 
come may not have been different from that 
which would have occurred with a standard 
portacaval shunt. If this is so, the child in- 
curred the slight increase in operative risk 
which would attend the performance of a 
second vascular anastomosis. Balancing this 
added risk is the theoretical benefit which 
might derive from the possibility that the 
total hepatic blood flow was less severely 
reduced than would result from a porracaval 
shunt. 
The ultimate prognosis in this case is not 
known. Both before and after the operation, 
there has been evidence of serious and con- 
tinued liver disease. The combination of 
portal cirrhosis with Type IIIB glycogen 
storage disease is extremely uncommon and 
may be fortuitous. Liver function has been 
stable since the time of operation. Histologi- 
cally, there appears to have been some pro- 
gression of the cirrhotic process and the 
rapidity with which this develops will be of 
far greater significance in limiting survival 
than the metabolic defect. 
SUMMARY 
An investigation was conducted of the in- 
fluence of portacaval transposition upon car- 
bohydrate metabolism in 45 dogs. I n  17 dogs, 
hepatic glycogen content was measured be- 
fore and from 45 to 75 days after trans- 
position. A reduction in glycogen content, 
principally in the TCA soluble fraction, was 
noted in 14 animals. The mean loss of total 
glycogen was 51 percent, and the mean loss 
of TCA soluble glycogen was 70 percent. In  
control animals hepatic deglycogenation did 
not occur. Despite the reduction in hepatic 
glycogen content, the animals were capable 
of glucagon-induced glycogenolysis using very 
small test doses. After transposition, a greater 
response to intraportal injection was noted as 
compared to that obtained with systemic 
venous infusions. 
Other alterations in carbohydrate metabo- 
lism were also measured. These included a 
reduction in the duration and magnitude of 
the hyperglycemic response to oral glucose 
loads. The profile of glycemic response under 
these conditions was studied, and demon- 
strated to be greatest in the portal vein, least 
in the peripheral venous blood, and of in- 
termediate magnitude in the peripheral ar- 
teries. 
Based upon the hepatic deglycogenating 
effect of portacaval transposition in dogs, 
this operation was used for the treatment of 
an 8%-year-old child with glycogen storage 
disease and concomitant portal cirrhosis. The 
portacaval transposition was performed in 
preference to a standard portacaval shunt. 
The enzyme defect in the patient was ex- 
tensively studied before and after transposi- 
tion. Prior to surgery, she was demonstrated 
to have Type IIIB glycogenosis (amylo-1,6- 
glucosidase deficiency confined to the liver). 
Eight and one half months after operation, 
the quantities of glycogen in liver and mus- 
cle and the enzyme activities showed no 
significant alteration. 
The clinical response to portacaval trans- 
position was gratifying. There has been a 
decrease in the hepatosplenomegaly, rapid 
growth, a diminution in the pre-existing hy- 
persplenism, and a considerable increase in 
the child's physical activity. Most of these 
benefits are ascribable to the effective portal 
deconipressive procedure. Whether any meta- 
bolic benefit derived from the portacaval 
transposition is problematical. 
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